Science Corporation implants its vision-restoring chip in first Stargardt disease patient
Original titleScience Corporation implants its vision-restoring chip in its first Stargardt disease patient
Science Corporation says its first Stargardt disease patient received the PRIMA vision-restoring implant in May during a trial at Sydney Eye Hospital in Australia. The patient saw a letter in the first rehabilitation session and read a word in the second.
CEO Max Hodak said the current 2 mm by 2 mm implant gives sharp, high-contrast black-and-white vision in a small central patch, and that a next-generation device is expected in humans within a year.
The report separates what the implant does now, a 2 mm patch with black-and-white central vision, from the company's longer-term claims, which helps readers gauge how far the technology has progressed.
Source: TechCrunch · AI · techcrunch.comPublished · added here